INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Core Insights - INmune Bio Inc. reported its financial results for the year ended December 31, 2024, and provided a business update, highlighting advancements in its clinical programs and financial performance [1][9]. Financial Performance - The net loss attributable to common stockholders for 2024 was approximately $42.1 million, compared to a loss of approximately $30.0 million in 2023 [9][25]. - Research and development expenses totaled approximately $33.2 million for 2024, up from approximately $20.3 million in 2023 [9][25]. - General and administrative expenses were approximately $9.5 million for 2024, slightly down from approximately $9.6 million in 2023 [9][25]. - The company had cash and cash equivalents of approximately $20.9 million as of December 31, 2024 [9][25]. Clinical Developments - The company completed enrollment for its Phase 2 trial (AD02 trial) focused on Early Alzheimer's Disease, exceeding the target enrollment with 208 patients [4]. - Interim analyses of the AD02 trial data showed a significant correlation (p<0.001) between baseline scores on the EMACC cognitive measure and the Clinical Dementia Rating-Sum of Boxes (CDR-SB) [4]. - The EMACC measure demonstrated high reliability with a correlation of 0.93 between screening and first study visit scores [4]. - CORDStrom™ received FDA's Rare Pediatric Disease Designation and Orphan Drug Designation for treating epidermolysis bullosa [4][7]. Product Platforms - XPro™ is a next-generation TNF inhibitor in clinical trials, targeting neuroinflammation to potentially improve cognitive function in neurological diseases [11]. - CORDStrom™ is a cell medicine platform utilizing human umbilical cord-derived mesenchymal stromal cells, showing promise for treating complex inflammatory diseases [14][15]. - INKmune® is designed to prime a patient's NK cells for cancer treatment, currently in a Phase I/II trial for metastatic castration-resistant prostate cancer [16][17]. Upcoming Milestones - Top-line cognitive results from the AD02 trial are expected in June 2025 [13]. - A Phase II trial of XPro™ for Treatment-Resistant Depression will begin enrollment soon [13]. - The company anticipates filing a Biologics License Application (BLA) for CORDStrom™ in 2025 or early 2026 [13].